Q4 EPS Estimate for Halozyme Therapeutics Boosted by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Leerink Partnrs lifted their Q4 2025 earnings estimates for shares of Halozyme Therapeutics in a research note issued to investors on Tuesday, February 18th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $1.66 per share for the quarter, up from their previous estimate of $1.57. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.72 per share.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million.

HALO has been the topic of several other reports. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Benchmark reaffirmed a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday. JMP Securities upped their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, HC Wainwright upped their price objective on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $57.44 on Friday. Halozyme Therapeutics has a 52 week low of $36.61 and a 52 week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm’s 50-day simple moving average is $53.26 and its 200 day simple moving average is $54.58. The firm has a market capitalization of $7.07 billion, a PE ratio of 16.75, a P/E/G ratio of 0.44 and a beta of 1.25.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

A number of large investors have recently bought and sold shares of HALO. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $29,000. CBIZ Investment Advisory Services LLC acquired a new position in Halozyme Therapeutics in the fourth quarter valued at about $29,000. Smartleaf Asset Management LLC raised its position in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $69,000. Finally, Parkside Financial Bank & Trust raised its position in shares of Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.